Roche's Avastin is top requested medicine in UK's cancer drugs fund PMLiVE Other drugs that received a high number of applications under the Cancer Drugs Fund included GSK's Tyverb (lapatinib), Roche's MabThera (rituximab) and Novartis' Afinitor (everolimus). Regarding the outcome of each application, Sir Michael said he was ... |
